Epizyme®‘s management team is composed of proven biopharma executives with a passion for creating innovative therapeutics for patients. A highly complementary team, we are proud to lead Epizyme’s exceptional organization.

Robert Bazemore
President and Chief Executive Officer 

160502_Epizyme_Robert_B_HiRes-4069Robert Bazemore has served as our President and Chief Executive Officer since September 2015. Prior to joining Epizyme, Mr. Bazemore served as Chief Operating Officer of Synageva through its acquisition in July 2015. Prior to that, he was President of Janssen Biotech, part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Mr. Bazemore began his career at Johnson & Johnson in 2002, and held numerous senior commercial positions, including leading the worldwide immunology portfolio strategy and the launches of multiple new products and indications. Prior to Johnson & Johnson, he worked at Merck & Co., Inc. for eleven years in roles of increasing responsibility. Mr. Bazemore received a B.S. in Biochemistry from the University of Georgia. He currently sits on the Board of Directors of Ardelyx, Inc.


Back to Top


Robert A. Copeland, Ph.D.
President of Research and Chief Scientific Officer

160502_Epizyme_HiRes-4565Robert A. Copeland, Ph.D. has served as our President of Research and Chief Scientific Officer since September 2008. Prior to joining Epizyme, Dr. Copeland was Vice President, Cancer Biology, of the Oncology Center of Excellence in Drug Discovery at GlaxoSmithKline (GSK). Before joining GSK, Dr. Copeland held scientific staff positions at Merck Research Laboratories of Merck and Bristol-Myers Squibb Company, a biopharmaceutical company, and a faculty position at the University of Chicago Pritzker School of Medicine. Dr. Copeland received a B.S. in chemistry from Seton Hall University, a Ph.D. in chemistry from Princeton University and did postdoctoral studies as the Chaim Weizmann Fellow at the California Institute of Technology.
Back to Top



Susan E. Graf, R.PH., MBA
Chief Business Officer 

Susan Graf joined Epizyme as our Chief Business Officer in April 2016. In this role she oversees and directs the implementation of Epizyme’s corporate strategy and leads corporate and business development and alliance management. An accomplished global biotechnology executive with more than 20 years of broad industry experience, Ms. Graf comes to us most recently from NPS Pharma where she held the position of Vice President, Corporate Development and Strategy before it was acquired by Shire in 2015. Ms. Graf was intimately involved in the company’s sale to Shire, in addition to serving on the executive team that transformed NPS Pharma into a global, commercial-stage, rare-disease biopharmaceutical company. During Ms. Graf’s tenure, NPS Pharma brought two rare disease products – Gattex® and Natpara® – to market. Prior to NPS Pharma, Ms. Graf spent nearly18 years at Roche in a number of leadership and executive positions in business development, commercial assessment, due diligence, mergers & acquisitions, marketing, market research, sales and manufacturing. Ms. Graf was recognized as a Healthcare Businesswomen’s Association Rising Star in 2011 and has been named to Purdue University’s ’40 Under 40’ list. She earned an M.B.A. from the Stern School of Business at New York University, and a Bachelor of Pharmacy degree from Purdue University.

Back to Top

Peter Ho, M.D., Ph.D.
Chief Medical Officer

160502_Epizyme_HiRes-3542Peter Ho, M.D., Ph.D. has served as Chief Medical Officer since September 2014. His prior pharmaceutical positions included Vice President of Oncology Development at Johnson & Johnson and Senior Vice President, Oncology Center of Excellence for Drug Development at GlaxoSmithKline. Dr. Ho is a board-certified pediatric hematologist/oncologist and was formerly a fellow at the Dana-Farber Cancer Institute, the National Cancer Institute (NCI) and the US Food and Drug Administration (FDA). He received a B.A. in biology from the Johns Hopkins University and an M.D. and Ph.D. (pharmacology) from the Yale University School of Medicine.
Back to Top




Matthew Ros
Chief Operating Officer 


Matthew Ros joined Epizyme in May 2016 as Chief Operating Officer. Mr. Ros joined Epizyme from Sanofi, where he was most recently Chief Operating Officer/Global Head of the Oncology Business Unit. While overseeing its $1.4 billion solid tumor and hematology franchise, he led its most recent restructuring and significantly contributed to the company’s revised business strategy. Prior to this role, Mr. Ros served in Genzyme’s Rare Disease business, leading its second largest franchise in Pompe Disease as its Vice President and Franchise head. Mr. Ros brings more than 25 years of experience in sales, marketing, franchise strategy and operations leadership in both global pharmaceutical and early-stage biotechnology companies. He received a B.Sc. in Business Administration from State University of New York, College at Plattsburgh.

Back to Top


Andrew E. Singer
Executive Vice President and Chief Financial Officer


Andrew E. Singer has served as our Executive Vice President, Finance and Administration, Chief Financial Officer and Treasurer since February 2015. Prior to joining us, from 2004 to January 2015, Mr. Singer served in increasing levels of responsibility in the Health Care Investment Banking Group at RBC Capital Markets Corporation, or RBC, an investment bank, serving as a Managing Director from 2007 to 2015. Prior to joining RBC, Mr. Singer worked at Petkevitch & Company, co-founded MVC Capital, and worked at Robertson, Stevens & Co, The Shansby Group and The Blackstone Group. Mr. Singer serves on the board of directors of the J.F. Kapnek Trust. Mr. Singer received a B.A. from Yale University and an M.B.A. from Harvard University Graduate School of Business.